このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ORIC Pharmaceuticals マネジメント

マネジメント基準チェック /44

ORIC Pharmaceuticals'の CEO はJacob Chackoで、 May2018年に任命され、の在任期間は 6.08年です。の年間総報酬は$ 3.15Mで、 18.9%給与と81.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.08%を直接所有しており、その価値は$ 5.42M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と4.2年です。

主要情報

Jacob Chacko

最高経営責任者

US$3.2m

報酬総額

CEO給与比率	18.9%
CEO在任期間	6.1yrs
CEOの所有権	1.1%
経営陣の平均在職期間	5.1yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

May 08

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Jan 18

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Sep 27

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Jan 24

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Oct 14

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Oct 08

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

Aug 11

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 24

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Apr 16

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Jan 01

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

Dec 21

Oric Pharma prices stock offering at $23

Nov 13

CEO報酬分析

ORIC Pharmaceuticals の収益と比較して、Jacob Chacko の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$102m
Dec 31 2023	US$3m	US$596k	-US$101m
Sep 30 2023	n/a	n/a	-US$93m
Jun 30 2023	n/a	n/a	-US$93m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$4m	US$572k	-US$89m
Sep 30 2022	n/a	n/a	-US$91m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	US$7m	US$536k	-US$79m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$91m
Mar 31 2021	n/a	n/a	-US$81m
Dec 31 2020	US$6m	US$489k	-US$74m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$672k	US$456k	-US$27m
Dec 31 2018	US$2m	US$290k	-US$21m

報酬と市場: Jacobの総報酬 ($USD 3.15M ) は、 US市場 ($USD 2.45M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jacobの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jacob Chacko (45 yo)

6.1yrs

在職期間

US$3,153,083

報酬

Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Heyman	Co-Founder	9.3yrs	US$186.87k	0.34% $ 1.6m
Jacob Chacko	President	6.1yrs	US$3.15m	1.08% $ 5.1m
Dominic Piscitelli	Chief Financial Officer	4.8yrs	US$1.45m	0.12% $ 587.5k
Pratik Multani	Chief Medical Officer	5.8yrs	US$1.51m	0.035% $ 166.9k
Charles Sawyers	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Scott Lowe	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Lori Friedman	Chief Scientific Officer	4.9yrs	データなし	データなし
Christian Kuhlen	General Counsel	4.2yrs	データなし	データなし
Daniel Iazzetti	VP & Head of People	1.8yrs	データなし	データなし
Edna Chow Maneval	Senior Vice President of Clinical Development	5.3yrs	データなし	データなし
Matthew Panuwat	Chief Business Officer	5.6yrs	データなし	データなし

5.1yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: ORICの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Heyman	Co-Founder	9.3yrs	US$186.87k	0.34% $ 1.6m
Jacob Chacko	President	6.1yrs	US$3.15m	1.08% $ 5.1m
Charles Sawyers	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Scott Lowe	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Laurence Lasky	Member of Scientific Advisory Board	no data	データなし	データなし
Angie You	Independent Director	2.6yrs	US$140.37k	0% $ 0
Lori Kunkel	Independent Director	4yrs	US$133.87k	0.030% $ 143.7k
Mardi Dier	Independent Director	4.3yrs	US$147.87k	0% $ 0
Steven Hoerter	Independent Indepdnent Director	2.8yrs	US$141.37k	0% $ 0

4.2yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: ORICの取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

ORIC Pharmaceuticals マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Independent Director exercised options to buy US$181k worth of stock.

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

President notifies of intention to sell stock

President notifies of intention to sell stock

President exercised options and sold US$125k worth of stock

President notifies of intention to sell stock

Recent updates

Independent Director exercised options to buy US$181k worth of stock.

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Price target increased by 9.3% to US$19.13

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

President notifies of intention to sell stock

Price target increased by 7.7% to US$17.50

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

President exercised options and sold US$125k worth of stock

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Price target increased by 12% to US$15.14

President notifies of intention to sell stock

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped from Russell 2000 Dynamic Index

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

President recently bought US$1.3m worth of stock

Price target decreased to US$14.00

Price target decreased to US$14.00

Price target decreased to US$28.00

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals, Inc. Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals, Inc. Presents Data Supporting the Therapeutic Potential of ORIC3 in Multiple Myeloma At the American Society of Hematology (ASH) Annual Meeting

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Price target decreased to US$33.00

ORIC Pharmaceuticals, Inc. Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

President notifies of intention to sell stock

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals, Inc. Announces Initial Data from an Ongoing Phase 1B Study Evaluating Oric-10

Independent Director & Member of Scientific Advisory Board Richard Scheller has left the company

ORIC Pharmaceuticals, Inc. Reports Initial Clinical Data Being Presented at ASCO from Phase 1B Trial of ORIC-101 in Combination with Nab-Paclitaxel

ORIC Pharmaceuticals EPS beats by $0.04

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

President notifies of intention to sell stock

New 90-day low: US$28.36

ORIC Pharmaceuticals, Inc. Provides Corporate Update

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

New 90-day high: US$36.60

New 90-day high: US$26.00

Oric Pharma prices stock offering at $23

ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc

New 90-day low: US$19.75

ORIC Pharmaceuticals, Inc. announced that it expects to receive funding from a group of investors

New 90-day low - US$22.10

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

マネジメント基準チェック /44